ArticleScientific reports2025
Berberine alleviates the proliferation and metastasis of ESCA by promoting CCDC18-AS1 expression based on bioinformatics and in vitro experimental verification.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although berberine exhibits anticancer activity, its mechanistic role in esophageal cancer (ESCA) remains unclear. Long non-coding RNAs (lncRNAs) expression profiling was conducted on berberine-treated and control ESCA TE-1 cells, identifying differentially expressed lncRNAs. Prognostic lncRNAs were selected through integration with the TCGA database, followed by the construction of a prognostic nomogram. In vitro assays and bioinformatics analyses were performed to validate berberine's impact on cell proliferation, metastasis, and key lncRNAs. Berberine treatment significantly altered lncRNA expression in TE-1 cells, with 344 upregulated and 235 downregulated lncRNAs. The expression of CCDC18-AS1, TBILA, and LINC02084 was associated with poorer overall survival (OS) and served as independent prognostic factors in ESCA. The nomogram accurately predicted 1-, 3-, and 5-year OS rates. Berberine inhibited TE-1 cell proliferation, migration, and invasion, primarily through the upregulation of CCDC18-AS1 expression. Genes co-expressed with CCDC18-AS1 were enriched in mRNA processing, RNA splicing, spliceosome, and mRNA surveillance pathways. Among these, overexpression of PCMTD2 and AL391840.2 represented risk factors, while RBM43 and LRIG2 were identified as protective factors in ESCA. Berberine may inhibit ESCA progression by modulating CCDC18-AS1 expression, thereby improving patient prognosis.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.